Jazz Pharmaceuticals acquires Chimerix for approximately US$935 million in cash
Through the acquisition Jazz Pharmaceuticals gains access to dordaviprone, a novel small molecule therapy in development for H3 K27M-mutant diffuse glioma in children and young adults. The transaction has been approved by both companies and is expected to close in Q2 of this year.
The acquisition sees Jazz Pharmaceuticals gain